Business Description
Standard BioTools Inc
NAICS : 423450
SIC : 5047
ISIN : US34385P1084
Total Employee Number:
389Description
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 16.97 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.42 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -0.24 | |||||
Beneish M-Score | 5.92 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -43.6 | |||||
3-Year EBITDA Growth Rate | 53.4 | |||||
3-Year EPS without NRI Growth Rate | 50.9 | |||||
3-Year FCF Growth Rate | 43.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 20.98 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 18.31 | |||||
9-Day RSI | 26.6 | |||||
14-Day RSI | 33.17 | |||||
3-1 Month Momentum % | -10.51 | |||||
6-1 Month Momentum % | -22.18 | |||||
12-1 Month Momentum % | -29.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.1 | |||||
Quick Ratio | 8.8 | |||||
Cash Ratio | 8.39 | |||||
Days Inventory | 183.45 | |||||
Days Sales Outstanding | 63.82 | |||||
Days Payable | 64.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -69.4 | |||||
Shareholder Yield % | 6.12 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 50.49 | |||||
Operating Margin % | -74.04 | |||||
Net Margin % | 100.37 | |||||
EBITDA Margin % | -78.81 | |||||
FCF Margin % | -97.61 | |||||
OCF Margin % | -94.92 | |||||
ROE % | 18.07 | |||||
ROA % | 14.49 | |||||
ROIC % | -14.43 | |||||
3-Year ROIIC % | 28 | |||||
ROC (Joel Greenblatt) % | -48.83 | |||||
ROCE % | -14.33 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 2.94 | |||||
Price-to-Owner-Earnings | 5.43 | |||||
PS Ratio | 2.94 | |||||
PB Ratio | 0.47 | |||||
Price-to-Tangible-Book | 0.47 | |||||
EV-to-EBIT | 2.7 | |||||
EV-to-Forward-EBIT | 44.85 | |||||
EV-to-EBITDA | 2.92 | |||||
EV-to-Forward-EBITDA | 44.85 | |||||
EV-to-Revenue | -2.3 | |||||
EV-to-Forward-Revenue | 3.32 | |||||
EV-to-FCF | 2.36 | |||||
Price-to-GF-Value | 0.91 | |||||
Price-to-Median-PS-Value | 1.38 | |||||
| Price-to-Net-Current-Asset-Value | 0.59 | |||||
| Price-to-Net-Cash | 0.65 | |||||
Earnings Yield (Greenblatt) % | 37.04 | |||||
FCF Yield % | -32.55 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LAB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Standard BioTools Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 84.597 | ||
| EPS (TTM) ($) | 0.22 | ||
| Beta | 1.2159 | ||
| 3-Year Sharpe Ratio | -0.38 | ||
| 3-Year Sortino Ratio | -0.51 | ||
| Volatility % | 58.13 | ||
| 14-Day RSI | 33.17 | ||
| 14-Day ATR ($) | 0.056582 | ||
| 20-Day SMA ($) | 0.79193 | ||
| 12-1 Month Momentum % | -29.54 | ||
| 52-Week Range ($) | 0.6336 - 1.72 | ||
| Shares Outstanding (Mil) | 392.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Standard BioTools Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Standard BioTools Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 | In 76 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 76 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 0.82 (-5.69%) | ||
| General meeting for 2026 | 2026-06-17 11:30 | 0.83 (-0.99%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 0.98 (+4.71%) | ||
| Annual report for 2025 | 2026-03-16 | 0.93 (+0.75%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-24 | 1.11 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-04 | 1.24 (+3.33%) | ||
| Second quarter earnings results for 2025 | 2025-08-11 | 1.31 (+1.16%) | ||
| General meeting for 2025 | 2025-06-18 08:30 | 1.02 (-5.56%) |
Show
Entries
Standard BioTools Inc Frequently Asked Questions
What is Standard BioTools Inc(LAB)'s stock price today?
The current price of LAB is $0.65. The 52 week high of LAB is $1.72 and 52 week low is $0.63.
When is next earnings date of Standard BioTools Inc(LAB)?
The next earnings date of Standard BioTools Inc(LAB) is 2026-11-04 Est..
Does Standard BioTools Inc(LAB) pay dividends? If so, how much?
Standard BioTools Inc(LAB) does not pay dividend.
Guru Commentaries on NAS:LAB
No articles.
Press Release
Articles on Standard BioTools Inc
Is Standard BioTools Inc (LAB) Overvalued After Q2 Loss? EPS: -$0.21, Revenue: $20.1M -- GF Score: 33/100
Aug 07, 2026
BlackRock, Inc. Reduces Standard BioTools Inc (LAB) Stake -- Shares Remain 47% Overvalued on GF Value
Aug 06, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers